Welcome
HPT/Axis is developing enclomiphene, an isomeric form of clomiphene, for new clinical indications, in a long neglected disorder with no FDA approved treatment, potential to be first-in-class thus becoming the standard of care treatment, in a large market, and protected by method-of-use patents. For enclomiphene, the immediate business opportunity is the treatment of the adverse [...]